Differences in sex- and age-associated mortality in patients with anti-MDA5-positive dermatomyositis

Mod Rheumatol. 2023 Aug 25;33(5):975-981. doi: 10.1093/mr/roac091.

Abstract

Objectives: The effect of sex and age on the outcomes of patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5+ DM) remains unclear. This study aimed to investigate the impact of sex and age on the prognosis of patients with MDA5+ DM.

Methods: We included 251 patients (women, 156; men, 95), who were newly diagnosed with MDA5+ DM between 2014 and 2021. The outcome was 6-month all-cause mortality after the diagnosis of interstitial lung disease. Cox regression analysis was used to assess the mortality. Adjusted restricted cubic spline analysis was performed to explore the non-linear relationship between age and outcomes.

Results: The 6-month mortality rates of women and men were 36.5% and 46.3%, respectively. Multivariate Cox regression revealed that ≥60 years of age was significantly associated with the risk of death (hazard ratio, 2.43; 95% confidence interval, 1.02-5.78). The trend of the risk of 6-month mortality in men was relatively flat until 54 years and increased rapidly afterwards (hazard ratio, 1.14; 95% confidence interval, 1.01-1.29). In contrast, the 6-month mortality rate showed a low linear increasing trend with age among females.

Conclusions: Patients with MDA5+ DM, who received contemporary treatment, had unfavourable outcomes. The 6-month mortality risk increased with age, particularly in male patients aged >54 years.

Keywords: Age; anti-MDA5 antibody; dermatomyositis; mortality; sex.

MeSH terms

  • Autoantibodies
  • Dermatomyositis* / complications
  • Dermatomyositis* / diagnosis
  • Female
  • Humans
  • Interferon-Induced Helicase, IFIH1
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies

Substances

  • Interferon-Induced Helicase, IFIH1
  • Autoantibodies